← Holders
Boxer Capital Management, LLC
What Boxer Capital Management, LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2018299 · Filed Nov 16, 2026
- Positions
- 47
- Reported value
- $1.2B
- Opened
- 12
- Closed
- 28
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Mar 31, 2025$332.5M28 positions
- Jun 30, 2025$198.7M20 positions
- Sep 30, 2025$313.7M34 positions
- Dec 31, 2025$456.9M45 positions
- Mar 31, 2026$761.7M54 positions
- Jun 30, 2026$1.3B63 positions
- Sep 30, 2026$1.2B47 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
TNGXTango Therapeutics, Inc. | 10.5M | −3.2% | $262.6M | 22.8% |
KODKodiak Sciences Inc. | 1.5M | ±0% | $140.1M | 12.2% |
RVMDRevolution Medicines, Inc. | 500K | ±0% | $102.6M | 8.9% |
KYMRKymera Therapeutics, Inc. | 524.6K | +22.2% | $58.6M | 5.1% |
REPLReplimune Group, Inc. | 4.3M | +7.4% | $56.6M | 4.9% |
ABVXAbivax S.A. | 475K | −21.5% | $47M | 4.1% |
SRZNSurrozen, Inc. | 1.4M | +23.1% | $43.8M | 3.8% |
CORTCorcept Therapeutics Inc | 335.5K | ±0% | $38.7M | 3.4% |
PGENPrecigen, Inc. | 4.3M | −16.1% | $37M | 3.2% |
QUREuniQure N.V. | 1.4M | −5.3% | $34.4M | 3% |
DFTXDefinium Therapeutics, Inc. | 683.6K | −31.5% | $26M | 2.3% |
AMLXAmylyx Pharmaceuticals, Inc. | 893.2K | +11.6% | $26M | 2.3% |
SYRESpyre Therapeutics, Inc. | 283.1K | +183.1% | $25.2M | 2.2% |
PTGXProtagonist Therapeutics, Inc | 170K | ±0% | $24M | 2.1% |
CELCCelcuity Inc. | 286.2K | −31.3% | $22.8M | 2% |
IRDOpus Genetics, Inc. | 4.5M | +61.1% | $21.9M | 1.9% |
QTTBQ32 Bio Inc. | 2.6M | −18.2% | $21.3M | 1.9% |
URGNUroGen Pharma Ltd. | 500K | ±0% | $20.3M | 1.8% |
ACHVAchieve Life Sciences, Inc. | 2.2M | New | $17.4M | 1.5% |
CCCCC4 Therapeutics, Inc. | 4.2M | New | $13.8M | 1.2% |
TRAXFirst Tracks Biotherapeutics, Inc. | 240K | New | $8.5M | 0.7% |
STTKShattuck Labs, Inc. | 1.2M | +17.5% | $8M | 0.7% |
SABSSAB Biotherapeutics, Inc. | 2.5M | New | $7.9M | 0.7% |
CGEMCullinan Therapeutics, Inc. | 450K | New | $6.9M | 0.6% |
CTNMContineum Therapeutics, Inc. | 494K | ±0% | $6.6M | 0.6% |
CYTKCytokinetics Inc | 100K | ±0% | $6.6M | 0.6% |
PALIPalisade Bio, Inc. | 4.8M | ±0% | $6.5M | 0.6% |
CAPRCapricor Therapeutics, Inc. | 642.8K | −53.9% | $6.1M | 0.5% |
ETRAElectra Therapeutics, Inc. | 450K | New | $5.1M | 0.4% |
ANTXAN2 Therapeutics, Inc. | 944K | +26.0% | $5M | 0.4% |
MAZEMaze Therapeutics, Inc. | 175.5K | New | $4.8M | 0.4% |
EDSAEdesa Biotech, Inc. | 937.4K | +357.3% | $3.9M | 0.3% |
RLAYRelay Therapeutics, Inc. | 200K | −55.6% | $3.6M | 0.3% |
KZIAKazia Therapeutics Ltd | 371.5K | −33.7% | $3.6M | 0.3% |
ATTOAttovia Therapeutics, Inc. | 200K | New | $3.4M | 0.3% |
PMVPPMV Pharmaceuticals, Inc. | 2.1M | New | $3.4M | 0.3% |
CRESCENT BIOPHARMA INC.COM | 226.8K | −50.0% | $3.3M | 0.3% |
ZNTLZentalis Pharmaceuticals, Inc. | 1M | New | $2.8M | 0.2% |
SRPTSarepta Therapeutics, Inc. | 150K | ±0% | $2.7M | 0.2% |
ALLOAllogene Therapeutics, Inc. | 1.5M | ±0% | $2.4M | 0.2% |
NRIXNurix Therapeutics, Inc. | 100K | ±0% | $2.4M | 0.2% |
SIONSionna Therapeutics, Inc. | 391.7K | New | $2.1M | 0.2% |
CLNNClene Inc. | 477.5K | ±0% | $1.9M | 0.2% |
ACRSAclaris Therapeutics, Inc. | 300K | New | $1.6M | 0.1% |
MISTMilestone Pharmaceuticals Inc. | 666.7K | ±0% | $577.1K | 0.1% |
NMRANeumora Therapeutics, Inc. | 954.1K | −52.3% | $568.8K | 0.1% |
KPTIKaryopharm Therapeutics Inc. | 127.5K | −57.8% | $155.6K | 0.1% |